4)510//6+10,-'7//,-'81)'9+,)%' :6+;,&%;1-&'%)'%('?@@A' … · 2018. 9. 18. · ^,1#"$#%-/)(d,#'!sind heterogene biochemische Stoffe, welche die Informationen zwischen Nervenzellen=

!"#$#%&'()'*%+),-'.,#'!,#%-/$%0$1-&'23#'4)510//6+10,-'7//,-'81)'9+,)%':"6+;,&%;1-&'%)'<=>%('?@@A'

B#;,($/&#155,'BC:DE7(-2%6+,'BFGH($I$/J1-.'B12),#F/%)F,($//$K#1-&'

'4LC'M@''NOP@=@QOPA=A''

!"#/$,001-&'•  !"#$%&'#$(")*)+&$,)%%&"%-..$•  D$1.(1)'.,#'>,.(8(-'(-'R,#0(-S'7//,-'1-.'TKU-&,-'•  O%6+%#8$%1/;(0.1-&'(-'7//0(-&,-S'93;(-&,-'1-.'7//,-'•  O%6+I#8G-'23#'V(-.,#J'1-.'W1&,-.5/X6+(%$#(,'E'Y#8$0(6+,'

Z/X6+"$+,#%5(,S'%F$1,00'(-'[,($,#;(0.1-&'81)'>%/$,#'"2'Z/X6+"$#%1)%$"0"&XE\-(H,#/($I$']3#(6+'

•  ^(,.,#&,0%//,-'(-',(&,-,#'Z#%_(/'/,($'MPP`S'81-I6+/$'(-'.,#'R(/)%#6F/$#%a,'<b'S'c,$8$'(-'.,#'>"0$F,/$#%a,'?PE!(00%'V"55,#/'''+d5NEEeee=5#%_(/J8()),#)%--=-,$'

!,#+,(#%$,$S'8e,('DK+-,S'MA'1-.'?f'W%+#,'

C%/'(/$'/(6+,#g'

•  C(,'B12),#F/%)F,($/JC,h8($J:X5,#%FGH($I$/JD$K#1-&''(/$'F,(-'i>".,JV#%-F+,($jS'/(,'(/$'%16+'-(6+$',#21-.,-'e"#.,-S'1)'H,#/6+(,.,-,'9+,#%5(,-'1-$,#k/'!"0F'81';#(-&,-='

•  MA`<':"l)%--N'!"#$%&'$())#*+#'#$,'•  MAAM'D6+,#52N'iC-.%/0+(*./1#%2$$#.#/3%-*.%45(67.'#%

8/39*/:4#%&##*#3.';$(37,%

•  MP@?'DG00N'7#2"#/6+1-&'H"-'V(-.,#-')($' '!"#<#:'.%/3%=>$-*%?>3'$>*,%

•  MPMb'L8,#-XN'3;,#'!&:4)#$#$@/#4A-$#%B/39#$,%•  MPfb'R#%.0,XN'7#/$;,/6+#,(;1-&'.,#'[(#F1-&'H"-'DG)10%-8(,-'

75(.,)("0"&(,'

•  45(67.'#%C#$4-*'#3..';$(37%A#/%B/39#$3%/0%

D$(39.:4(*-*'#$%EFGHIJ%

•  KGL%0-*%45(67#$%A#/%M(37#3%-*.%A#/%=59:4#3%

•  45(67%NA#$9-(#$39%(39%@O%PO%(37N3.Q7#$%C#$*-(<%RA#.>39#$.%-3%.>7O%&:43/S.'#**#3%9#$%

T3')/:8*(37%ET3')/:8*(37.7#<54$9(37J%

BC:D'Z#";0,),'

•  D$K#1-&,-'.,/'m,#-H,#+%0$,-/'1-.'.,/'D"8(%0H,#+%0$,-/'

•  O0(,a,-.,'n;,#&I-&,'•  R,0%/$1-&'.,/'\)2,0./'(-'%00,-'C(),-/("-,-N'– 70$,#-''– m,+#,#'– >($/6+30,#'

7#/6+,(-1-&/;(0.'

•  !"#$%&'()*#&)'+,%U%0-37#*39#%V(<0#$8.-08#/'%(39%

W/#*7#$/:4'#'4#/'%9#.%C#$4-*'#3.%

–  O036+G&F,($/2,+0,#S'!,#&,a0(6+F,($S'B;0,-F;%#F,($'.1#6+'I1a,#,'*,(8,'•  -./'(#)01+,2,%U%0>'>$/.:4#%X3$(4#%9#$%B/39#$%

–  :,#1)8%55,0-S'H='%='(-'1-5%//,-.,-'D($1%G"-,-S'D6+e(,#(&F,($,-'/(6+')($',(-,#'D%6+,'(-'*1+,'81';,/6+Io(&,-'

•  3&/$4*+1+,2,%U%1>$.:43#**#.%(39%(3A#9-:4'#.%C#$4-*'#3%–  \-$,#;#,6+,-'H"-'D5(,0,-'1-.'T,/5#I6+,-'

Z#";0,),'

•  &'539/7#%B>3Y/8'#%0/'%%Z#@(7.+#$.>3#3%

•  T$@/#4(37..:4)/#$/78#/'#3%•  [$>A*#0-Q.:4#$%X07-37%0/'%D*#/:4-*'$/7#3%

•  &:4*#:4'#%&:4(**#/.'(37#3%•  \#7-Q1#.%&#*A.'A/*9%•  T$4;4'#%D#<-4$%9#$%&(:4'G%(39]>9#$%9/..>@/-*#3%T3')/:8*(37%

[,($,#,'Z#";0,),'

•  -**7#0#/3#$#%V(<0#$8.-08#/'..:4)/#$/78#/'#3%

–  )"$"#(/6+,'\-#1+,';,('MpqS''

–  \-F"-8,-$#(,#$+,($';,('MPq''•  B>0>$A/9/'5'%

–  D$K#1-&,-'.,/'D"8(%0H,#+%0$,-/'r6%='p@'qs'–  "55"/(G"-,00,/'!,#+%0$,-'r6%='`@'qs'–  C,5#,//("-,-'r6%='f@'qs'–  B-&/$'r6%=f@'qs'–  m,#-/$K#1-&,-'r6%='MM'qs'–  9(6/$K#1-&S',(-/6+0(,a0(6+'9"1#,d,JDX-.#")''

R,%6+$,g'

•  C(,'+I1h&/$,'5/X6+(%$#(/6+,'V")"#;(.($I$'/(-.'D$K#1-&,-'.,/'D"8(%0H,#+%0$,-/'1-.'1)/6+#(,;,-,'7-$e(6F01-&//$K#1-&,-=''

•  7)"G"-%0,'D$K#1-&,-'e,#.,-'%)'+I1h&/$,-'3;,#/,+,-='

7-$e(6F01-&/&,2I+#.1-&,-Em%-&8,($,-$e(6F01-&'

•  F,(-,'/"&,-%--$,-'7-_$e(6F01-&/%12&%;,-'r]=R='D6+10%;/6+01//s'

•  F,(-,'/"8(%0,'V")5,$,-8'r8=R='V"-t(F$;,eI0G&1-&s'

•  B1//6+01a'H"-'2K#.,#0(6+,-'D"8(%0F"-$%F$,-'r8=R='O#,1-./6+%o,-s'

•  D,0,FG"-/)%a-%+),-'r8=R='[(,.,#+"0,-',(-,#'V0%//,s'

T#1-./I$8,'

•  W,.,)'V(-.'/"00',(-,'%-&,),//,-,'9,(0+%;,'%)'\-$,##(6+$'1-.'%)'D"8(%00,;,-'.,#'V0%//,')K&0(6+'/,(-'

•  ^(6+$'c,.,'!,#+%0$,-/%1lI00(&F,($'(/$',(-,'V#%-F+,($'

•  BCDE:VD'(/$'F,(-,'7-$/6+10.(&1-&S',/',#)K&0(6+$'-1#',(-';,//,#,/'!,#/$I-.-(/'.,#'D($1%G"-'

R,&#(l/;,/G))1-&'

•  B12),#F/%)F,($'1-.'V"-8,-$#%G"-'rBd,-G"-'%-.'6"-6,-$#%G"-s'),(-$'.(,'B1/#(6+$1-&'r%FGHS5%//(Hs'.,/'R,e1a$/,(-/'%12',(-'7#2%+#,-.,/S'V"-8,-$#%G"-'),(-$'.%/'H,#/%)),0$,'C%;,(;0,(;,-='

•  B-$#(,;'r'T#1-.%FGH($I$s'),(-$'.(,'()'B1/.#16F'/(6+'F1-.&,;,-.,'T#1-.%FGH($I$',(-,/'>,-/6+,-''

•  B1/'B00&,),(-,'Z/X6+"5%$+"0"&(,S'L+#(/G%-'D6+%#2,d,#S'9+(,),'[(//,-/6+%o'MPPM''

Z#%_(/,)52%-&'

V%--'7#8(,+1-&'.%/':(#-'F"-/$#1(,#,-u'VK--,-'e(#'V(-.,#-';,('.,#'7-$e(6F01-&'(+#,/'C,-F%55%#%$/'-,1#".(.%FG/6+'+,02,-u'

>%6+$'C,-F,-'&036F0(6+S'1-.'e,--'c%S'e(,')3//$,')%-'.,-F,-S'1)',/'81'e,#.,-u'7(-'9#%(-(-&N'R,-,--,-'D(,'.(,'D6+#(o2%#;,'

c,.,/',(-8,0-,-'["#$,/'-%6+,(-%-.,#'

>,+#F")5"-,-$,-)".,00'

•  'j%0,#$-,//v''wB12),#F/%)F,($/%FGH(,#1-&''

•  j/,0,6GH,'%d,-G"-v'w/,0,FGH,'E'2"F1//(,#$,''B12),#F/%)F,($''

•  j.(H(.,.'%d,-G"-v'w&,$,(0$,'B12),#F/%)F,($'

•  j/1/$%(-,.'%d,-G"-v''w0I-&,#2#(/G&,'B12),#F/%)F,($S''C%1,#%12),#F/%)F,($'''

4LC'V0%//(hF%G"-'[:x'F90.- !Hyperkinetische Störungen-! Aufmerksamkeits-Defizit-Syndrom mit

Hyperaktivität ( ADHS) „ Zappelphilipp“, früher auch „ HKS“!

F90.0 Einfache Aktivitäts- und Aufmerksamkeitsstörung ! !! F90.1 !Hyperkinetische Störung des Sozialverhaltens ! !! F90.8 !Sonstige hyperkinetische Störungen! !! F90.9 !Hyperkinetische Störung, nicht näher bezeichnet ! !!

F98.8 !Sonstige näher bezeichnete Verhaltens- und emotionale Störungen mit Beginn in der Kindheit und Jugend, darunter Aufmerksamkeitsstörung ohne Hyperaktivität ->Aufmerksamkeits-Defizit-Syndrom ( ADS) „ Hans-Guck in die Luft“,“ der fliegende Robert“, „Träumer“'

B1/'.,)'D$#1ee,05,$,#'^_A%9#$%[4/*/++%4#('#%.Q**%)>4*%A#/%P/.:4#%

./'@#3%)/**%`,%

V*.>%.+$-:4%/3%#$3.'#0%P>3%9#$%[-+-%@(%

.#/3#0%&>43R%

X39%9/#%=(S#$%A*/:8'#%.'(00%-(<%9#0%

7-3@#3%P/.:4%4#$(0O%

">:4%9#$%[4/*/++%4;$'#%3/:4'R%)-.%@(%/40%

9#$%C-'#$%.+$/:4'O%T$%7-(8#*'%(39%.:4-(8#*'R%

#$%'$-++#*'%(39%@-++#*'%-(<%9#0%&'(4*#%4/3%

(39%4#$O^[4/*/++R%9-.%0/a<5**'%0/$%

.#4$%b,OOOOOOOO='

'[(,'F")),-'.(,'y*%/,-';,$#,$,-'H,#;"$,-yJ''D6+(0.,#'(-'.(,'>(d,'.,/'*%/,-/u''

HEIßT ES NUR EINFACHES KOMPLIZIERT ZU MACHEN?!

:(#-,-$e(6F01-&J],($H,#0I12,'

'''7);#X"'Q'O,$1/'!^,1#"&,-,/,'Q'>(&#%G"-'Q'B_"&,-,/,'

''''O,$1/'Q'DI1&0(-&J!'DX-%5$"&,-,/,''

•  DI1&0(-&Q'V(-.+,($';(/'(-/'7#e%6+/,-,-%0$,#!>X,0(-(/(,#1-&'Q'^,#H,-8,00,0()(-%G"-'Q'DX-%5/,-,0()(-%G"-QDX-%5/,-2,/G&1-&''

^,1#"5+X/("0"&(,'B12),#F/%)F,($'F%--'H,#/6+(,.,-,-'B/5,F$,-'81&,e%-.$'e,#.,-N''

'x#$,-''

'O%#;,-'

'4-+%0$,-JJJJJJJJJJJJJJJ!''''

'T,#I1/6+,-S'9K-,-''

F%--'e(00F3#0(6+'1-.'1-e(00F3#0(6+'H,#0%&,#$'e,#.,-'

23+#$'81'),+#'-,1#"-%0,#'BFGH($I$'(-'5#()I#,-'1-.'/,F1-.I#,-'/,-/"#(/6+,-'B#,%0,-'

:,1$,'(/$'/6+102#,(g''

m(6+$'DG))1-&'7)"G"-'

[%/'(/$'e(6+G&u'

•  *,6+$8,(G&,/'7#F,--,-'H"-'*(/(F"),#F)%0,-'•  7#2%//,-'.,#'V(-.,#S'.,-,-'.1#6+'H"#;,1&,-.,'>%a-%+),-'&,+"02,-'e,#.,-'F%--'•  7#2%//,-'.,#'V(-.,#S'.(,';,+%-.,0$'e,#.,-'/"00$,-'•  DG&)%G/(,#1-&'.1#6+'i>,.(8(-%0(/(,#1-&j'H,#),(.,-='

7#F0I#1-&/%-/I$8,'

•  ^%+#1-&/)(d,081/I$8,'r-(6+$';,0,&$s'

•  :(#-/6+I.(&1-&'rus'•  D$K#1-&,-'.,/'^,1#"$#%-/)(d,#JD$"le,6+/,0/'

•  &,-,G/6+,'C(/5"/(G"-'•  D$K#1-&,-'.,#'D,0;/$#,&10%G"-'•  \-&3-/G&,'R,.(-&1-&,-'(-'.,#'\)e,0$'

^,1#"$#%-/)(d,#'

!sind heterogene biochemische Stoffe, welche die Informationen zwischen Nervenzellen= Neuronen über Kontaktstellen oder Synapsen weitergeben.!

!Ziel einer medikamentösen Therapie ist die Optimierung dieser Signalübertragung. !

!Die Konzentration ausgeschüttteter Neurotransmitter im synaptischen Spalt wird durch die Psychopharmaka erhöht.!

!Dadurch verbessert sich die Signalübertragung im verantwortlichen Netzwerk!

!1.) Methylphenidat (schnell- oder verzögert wirksam/ retardiert ) verzögert den Dopaminabbau. 2.) Atomoxetin (Strattera) ist ein hochselektiver Noradrenalinwiederaufnahmehemmer oder!! ! ! ! !NSRI ( Noradrenalin-Re-Uptake-Inhibitor)!

Z+%#)%F"$+,#%5(,'

•  81#'!,#)(-.,#1-&'+X5,#F(-,G/6+,#'1-.'!,#$#I1)$+,($/J'DX)5$"),'(-'.,#'D6+10,'r()'V(-.,#&%#$,-sS'(-'.,#'O%)(0(,'".,#'(-'%-.,#,-'\)&,;1-&,-=''

•  C%/'V(-.'(/$'%0/'%FGH,#'9,(0-,+),#'(-'.(,/,-'Z#"8,a',(-81;(-.,-='

Z+%#)%F"$+,#%5(,'

•  [(#F/%)F,($';,('6%='p@'q'

•  !,#0%12/F"-$#"00,'g'–  DX)5$"),'.,#'B12),#F/%)F,($//$K#1-&S'4)510/(H($I$'1-.':X5,#%FGH($I$''

–  D6+10(/6+,'m,(/$1-&,-'1-.'/6+10(/6+,/'!,#+%0$,-''–  R,8(,+1-&,-'81'T0,(6+%0$#(&,-''–  O#,(8,($%FGH($I$,-''

D$K#1-&/#,0,H%-$,'*%+),-;,.(-&1-&,-'r'Ms''

•  56/47(#07"89'(854,'(":8+"*;'*7"9'('<8%–  4-F"-/(/$,-$,/'7#8(,+1-&/H,#+%0$,-''– >%-&,0-.,'[I#),'(-'.,-'2%)(0(I#,-'R,8(,+1-&,-''

–  D5,8(h/6+,'R,eI0G&1-&//$#%$,&(,-'.,#'70$,#-'(-'F#(G/6+,-'7#8(,+1-&//($1%G"-,-''

–  D$K#1-&/F"-8,5$,'.,#'70$,#-S'(+#,'9+,#%5(,,#e%#$1-&,-'1-.'(+#,'R,#,($/6+%o'81#'%FGH,-'>($%#;,($'

– >,.(,-F"-/1)S'&,-%1',#2#%&,-'

D$K#1-&/#,0,H%-$,'*%+),-;,.(-&1-&,-'r?s''

•  3"%7(&#07"'"817"89'(8=>?$4'%%–  4-$,&#%G"-'.,/'V(-.,/'(-'.(,'T#155,''–  R,0%/$,-.,'R,.(-&1-&,-'()'V(-.,#&%#$,-E(-'.,#'D6+10,'r8=R='V0%//,-&#Ka,S'B-$,(0'H,#+%0$,-/%1lI00(&,#'V(-.,#s''

–  *,//"1#6,-'()'V(-.,#&%#$,-E(-'.,#'D6+10,'r8=R='V0,(-&#155,-1-$,##(6+$S'V0,(-&#155,-;,/6+Io(&1-&s''

–  D$K#1-&/F"-8,5$,'.,#'7#8(,+,#Em,+#,#S'(+#,'9+,#%5(,,#e%#$1-&,-'1-.'(+#,'R,#,($/6+%o'81#'%FGH,-'>($%#;,($='

B#;,($/%-/I$8,E4-$,#H,-G"-,-'8=R=N''

•  *,//"1#6,-')";(0(/(,#,-'– D$#,a5#IH,-G"-'– 7-$/5%--1-&/H,#2%+#,-'– 9#%(-(-&'D"8(%0,'V")5,$,-8'

– 9#%(-(-&'*"00,-h-.1-&'– D16+$5#IH,-G"-'

•  *36F),0.1-&,-',-$e(6F,0-'

](,0,'

•  m,#-,#2"0&'/(6+,#-'

•  D"8(%0,'4-$,&#%G"-'/$%;(0(/(,#,-'

•  DG&)%G/(,#1-&'H,#),(.,-'

[,&,'

•  [%6++,($'23#'.%/'Z#";0,)'2K#.,#-'

•  !,#-,$81-&'.,#'BF$,1#,'•  iO#3+e%#-/X/$,)j'

•  ^%6+/6+%1'– Z0%-,-'– :%-.,0-'– Z#32,-'– !,#;,//,#-'

D6+10(/6+,'4-$,#H,-G"-,-S'8=RN'

•  D$"55JD6+(0.''•  D(&-%0F%#$,-'•  R,/5#,6+1-&'1-.'D$#1F$1#(,#1-&'H"-',(-8,0-,-'

Z#";0,);,#,(6+,-'–  8=R='9%&,/50%-S'R,#12/50%-1-&S'C,$,FGH;"&,-',$6='

•  B-0,($1-&''–  /$#1F$1#(,#$'–  #,&,0&,0,($,$'–  .(#,F$'–  ,_50(8($'

R,e,&1-&/.#%-&'F%-%0(/(,#,-'

•  R"$,-&I-&,'•  V0%//,-.(,-/$,'•  :%-./6+),(6+0,#''r\)0,-F1-&'H"-'V0%55,#-')($'DGo,-s'

D$#1F$1#,-'/6+%l,-'

•  F,(-,'C(/F1//("-,-'•  F0%#,'!"#/6+#(o,-'•  -"-H,#;%0,'V"))1-(F%G"-'

B12),#F/%)F,($'+,#/$,00,-'

•  4-'.(,'T,&,-e%#$'81#36F+"0,-'•  VK#5,#F"-$%F$'•  %F1/G/6+,'D(&-%0,'•  B-F3-.(&1-&'H"-'B12#12,-'

Documents

4)510//6+10,-'7//,-'81)'9+,)%' :6+;,&%;1-&'%)'%('?@@A' … · 2018. 9. 18. · ^,1#"$#%-/)(d,#'!sind heterogene biochemische Stoffe, welche die Informationen zwischen Nervenzellen=